Coinfection

CROI 2015: Retrovirus Conference Now Underway in Seattle

The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place this week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com is on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).

alt

Read more:

CROI 2015: Retrovirus Conference Starts Monday in Seattle

The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place next week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com will be on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).

alt

Read more:

Coverage of the 2014 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.

Full listing by topic

The Liver Meeting website

12/2/14

alt

10. Hepatitis C Cures for HIV/HCV Coinfected and Advanced Liver Disease

New interferon-free direct-acting antiviral regimens have high cure rates for chronic hepatitis C patients who were previously considered "difficult to treat," including HIV/HCV coinfected people and patients with liver cirrhosis, decompensated liver disease, and liver transplant recipients. New treatment can now cure a majority of people even with multiple negative predictive factors.

alt

Read more:

AASLD 2014: Sofosbuvir + Simeprevir Shows Good Results in Real-World Use

Regimens containing sofosbuvir (Sovaldi) -- including sofosbuvir plus simeprevir (Olysio) -- work well for people with hepatitis C genotype 1 in real-world use, which to date has included some of the patients most urgently in need of treatment at the dawn of the interferon-free era, according to a pair of presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Sofosbuvir plus ribavirin alone is highly effective for people with genotype 2.

alt

Read more:

HCV Does Not Worsen Cognitive Impairment in HIV Positive People without Advanced Liver Damage

Coinfection with hepatitis C virus (HCV) does not appear to contribute to neurocognitive impairment in people with HIV who do not have advanced liver disease, according to results from the CHARTER study published in the December 10 online edition of Neurology.

alt

Read more:

AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection

AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most patients with HIV and hepatitis C virus (HCV) coinfection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.

alt

Read more:

Coverage of the 2014 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.

Full listing by topic

The Liver Meeting website

12/2/14

alt

AASLD 2014: HIV Positive People Have High Survival Rates After Liver Transplants Due to HCC

People with HIV -- most of whom were coinfected with hepatitis B or C -- generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with 5-year survival rates similar to those of HIV negative transplant recipients and better than those of people who underwent other types of liver cancer treatment, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more: